Published in Clin Chem on February 01, 2001
Obesity-related hypoferremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. J Am Diet Assoc (2008) 1.77
Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes (Lond) (2007) 1.59
Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening. Am J Hematol (2008) 0.88
Iron genes, iron load and risk of Alzheimer's disease. J Med Genet (2006) 0.84
EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet (2015) 0.81
Serum ferritin levels correlate with haemoglobin concentration: a report on 589 outpatients from a single centre. Blood Transfus (2007) 0.81
Clinical penetrance of C282Y homozygous HFE haemochromatosis. Clin Biochem Rev (2004) 0.81
Iranian hereditary hemochromatosis patients: baseline characteristics, laboratory data and gene mutations. Med Sci Monit (2012) 0.80
Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFE C282Y homozygosity. BMC Med Genet (2006) 0.78
Bone Mineral Density in Postmenopausal Women Heterozygous for the C282Y HFE Mutation. J Osteoporos (2016) 0.75
Effects of strain and age on hepatic gene expression profiles in murine models of HFE-associated hereditary hemochromatosis. Genes Nutr (2014) 0.75
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA (1995) 26.38
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA (1998) 23.39
Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA (1995) 20.12
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 14.57
Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA (1999) 10.77
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Standards for patient monitoring during anesthesia at Harvard Medical School. JAMA (1986) 3.72
Therapeutic intervention scoring system: a method for quantitative comparison of patient care. Crit Care Med (1974) 3.70
Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med (1999) 3.46
Therapeutic Intervention Scoring System: update 1983. Crit Care Med (1983) 3.20
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology (1998) 3.13
Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet (1994) 2.90
A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med (1999) 2.86
Haemochromatosis and HLA-H. Nat Genet (1996) 2.81
Survival, hospitalization charges and follow-up results in critically ill patients. N Engl J Med (1976) 2.80
Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol (1999) 2.41
Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index. Hepatology (1990) 2.30
Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology (1986) 2.30
HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med (1999) 2.10
Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol (1990) 2.01
Administrative guidelines for response to an adverse anesthesia event. The Risk Management Committee of the Harvard Medical School's Department of Anaesthesia. J Clin Anesth (1993) 1.94
Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet (2000) 1.89
Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology (1999) 1.83
High prevalence of coeliac disease in a population-based study from Western Australia: a case for screening? Med J Aust (2001) 1.77
EASL International Consensus Conference on Haemochromatosis. J Hepatol (2000) 1.76
Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA (1998) 1.73
Normal serum ferritin concentrations in precirrhotic hemochromatosis. N Engl J Med (1976) 1.68
Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet (2005) 1.68
Effects of information feedback and pulse oximetry on the incidence of anesthesia complications. Anesthesiology (1987) 1.58
Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology (1999) 1.58
The Australian Tobacco Research Foundation. Med J Aust (1988) 1.58
Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol (2000) 1.50
Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families. N Engl J Med (1967) 1.48
Localization of the hemochromatosis gene close to D6S105. Am J Hum Genet (1993) 1.46
An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive diisopropylfluorophosphate and chromium. Australas Ann Med (1967) 1.46
Results, charges, and benefits of intensive care for critically ill patients: update 1983. Crit Care Med (1984) 1.46
Domestic exposure to formaldehyde significantly increases the risk of asthma in young children. Eur Respir J (2002) 1.46
Verifying the (we hope) verified: reference checking in the Journal of Clinical Anesthesia. J Clin Anesth (1993) 1.43
Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut (1972) 1.41
The legal system and patient safety: charting a divergent course: the relationship between malpractice litigation and human errors. Anesthesiology (1999) 1.41
Population screening for HFE-associated haemochromatosis: should we have to pay for our genes? Intern Med J (2001) 1.40
Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology (1984) 1.37
Iron and coronary heart disease. BMJ (1993) 1.35
Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology (1998) 1.35
Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology (1998) 1.35
Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst (1985) 1.31
Enhanced drug metabolism in cigarette smokers. Br Med J (1976) 1.31
Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem (1990) 1.30
Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol (2003) 1.29
Hemochromatosis: 1980 update. Gastroenterology (1980) 1.29
Haemochromatosis after the discovery of HFE ("HLA-H") Gut (1997) 1.28
Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med (1998) 1.28
Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality. Gut (1970) 1.27
Guillain Barré syndrome during the pre-icteric phase of acute type B viral hepatitis. Aust N Z J Med (1975) 1.26
Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology (1993) 1.25
Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet (1987) 1.23
Human isoferritins: organ specific iron and apoferritin distribution. Br J Haematol (1975) 1.23
Demonstration of previously undetected hepatitis B viral determinants in an Australian Aboriginal population by monoclonal anti-hbs antibody radioimmunoassays. Lancet (1982) 1.23
First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut (2005) 1.22
Abnormality in tissue isoferritin distribution in idiopathic haemochromatosis. Nature (1974) 1.19
Cardiovascular effects of carbon dioxide in man. Anesthesiology (1974) 1.17
The pathogenesis of pulmonary edema in acute pancreatitis. Ann Surg (1975) 1.17
Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol (2001) 1.17
Iron storage disorders of the liver. Gastroenterology (1974) 1.17
Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol (1997) 1.16
Transferrin receptor distribution and regulation in the rat small intestine. Effect of iron stores and erythropoiesis. Gastroenterology (1990) 1.15
Evidence that the ancestral haplotype in Australian hemochromatosis patients may be associated with a common mutation in the gene. Am J Hum Genet (1995) 1.15
Haplotype analysis in Australian hemochromatosis patients: evidence for a predominant ancestral haplotype exclusively associated with hemochromatosis. Am J Hum Genet (1995) 1.14
Concordance of iron storage in siblings with genetic hemochromatosis: evidence for a predominantly genetic effect on iron storage. Hepatology (1993) 1.14
Recurrent hepatitis in patients receiving multiple halothane anesthetics for radium treatment of carcinoma of the cervix uteri. Gastroenterology (1970) 1.13
Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther (1979) 1.13
A comparison of intensive care in the U.S.A. and France. Lancet (1982) 1.13
Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J Hepatol (2000) 1.13
Evaluating outcome from intensive care: a preliminary multihospital comparison. Crit Care Med (1982) 1.13
Antibiotic resistance in Helicobacter pylori. Med J Aust (2000) 1.12
Cirrhosis of the liver. A comparative study of the four major aetiological groups. Med J Aust (1971) 1.12
Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res (2001) 1.09
Red cell survival in experimental cholestatic cholestatic jaundice. Br J Haematol (1968) 1.09
Evaluation of conjunctival pallor in the diagnosis of anaemia. J Trop Med Hyg (1986) 1.08
HLA typing in idiopathic hemochromatosis: distinction between homozygotes and heterozygotes with biochemical expression. Hepatology (1981) 1.08
A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient. Gut (2003) 1.08
Wilson's disease in an Australian aborigine. J Gastroenterol Hepatol (1991) 1.07
Iron overload. Semin Hematol (1982) 1.07
Perinatal risk factors for childhood Type 1 diabetes in Western Australia--a population-based study (1980-2002). Diabet Med (2007) 1.06
Red cell survival after Heterograft valve surgery. Br Med J (1968) 1.06
Idiopathic haemochromatosis in the Australian population: HLA linkage and recessivity. Hum Immunol (1981) 1.05
How well does a journal's peer review process function? A survey of authors' opinions. JAMA (1994) 1.05
A comparison of the cardiovascular effects of halothane, fluroxene, ether and cyclopropane in man: a resumé. Anesthesiology (1971) 1.05
Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology (1985) 1.05
The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology (1986) 1.04
Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem (2000) 1.04